Avapritinib 25 mg, 100 mg, 200 mg Suppliers & Bulk Manufacturers

Available Forms: Capsules

Available Strengths: 25 mg, 100 mg, 200 mg

Reference Brands: Ayvakyt (USA/EU)

Category: Oncology Cancer Care

Avapritinib is a targeted oncology therapy used to treat gastrointestinal stromal tumors (GIST) with PDGFRA exon 18 mutations. It works by inhibiting mutant tyrosine kinases, slowing tumor growth and controlling disease progression. Available as oral capsules in strengths of 25 mg, 100 mg, and 200 mg, Avapritinib is typically administered once daily under specialist supervision.

Product Description:

Avapritinib is a selective inhibitor of KIT and PDGFRA, designed specifically to bind the active conformation of these kinases. That design matters: gastrointestinal stromal tumours driven by the PDGFRA D842V mutation are resistant to imatinib, sunitinib and regorafenib, because those drugs bind the inactive conformation that the mutation destabilises. Avapritinib is effective where they are not.

It is used for gastrointestinal stromal tumour with a PDGFRA exon 18 mutation including D842V, and for advanced and indolent systemic mastocytosis, where the KIT D816V mutation drives mast cell proliferation. Response rates in D842V GIST were high in a population that previously had no effective option. Cognitive effects — memory impairment, confusion — are a characteristic and dose-related adverse effect, and intracranial haemorrhage is a warning, so platelet counts are monitored and it is avoided with low platelets. Nausea, oedema and anaemia are common.

Sourcing notes. Originator product, on patent, no generic. Mutation testing is a prerequisite and the eligible populations are genuinely small — D842V accounts for a few percent of GIST. Supply is through authorised distribution to specialist sarcoma and haematology centres.